Sinopharm Accord(200028.SZ)

China National Accord Medicines Sees 2025 Net Profit Up 64.2-89.1%

China National Accord Medicines Corp Ltd :SEES 2025 NET PROFIT UP 64.2-89.1%

The three major A-share indices of Shanghai and Shenzhen showed mixed performance in the first half of the day, with the commercial aerospace sector being hotly traded. NPEC rose nearly 6% on positive earnings news

The three major A-share indices showed mixed performance, with the Shanghai Composite Index slightly up 0.3%, the Shenzhen Component Index rising 0.2%, and the ChiNext Index down 0.2%. The RMB central parity rose to 6.9929 against the US dollar, and the People's Bank of China conducted reverse repos, with a net injection of 38.3 billion yuan. The commercial aerospace sector was hotly traded, with NPEC's stock price rising nearly 6%. Pharmaceutical commercial stocks performed well, with Yifeng Pharmacy hitting the daily limit. International gold prices rose, and related stocks generally rebounded

Pharmaceutical commercial stocks opened higher, with Yifeng Pharmacy hitting the daily limit, followed by DSL, Jointown, Hezong Medicine Easy-To-Buy Pharmaceutical, SYPM, and LBX. In terms of news, the Ministry of Commerce and 8 other departments issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry."

Build "Health Stations"! 9 departments issued documents to promote the high-quality development of the pharmaceutical retail industry

The Ministry of Commerce and 8 other departments jointly issued opinions to promote the high-quality development of the pharmaceutical retail industry, proposing 18 measures aimed at transforming pharmacies into "health service hubs." The measures include enhancing pharmaceutical service capabilities, optimizing the purchasing experience, participating in centralized procurement, and building a payment guarantee system, further strengthening the health service functions of retail pharmacies to better meet the medical and health needs of the people

Sinopharm Subsidiary Sinopharm Accord Reports Q3 Revenue Decline

Sinopharm Group Co. Ltd. reported that its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), experienced a revenue decline of 1.89% year-on-year, totaling RMB 18.33 billion for Q3 2025. However, total assets increased by 6.31% to RMB 50.56 billion, and equity attributable to shareholders rose by 4.30% to RMB 18.43 billion compared to the previous year.